Advertisement

Immune Response to HTLV-I and HTLV-II

  • Samantha S. Soldan
  • Steven Jacobson
Chapter
Part of the Infectious Disease book series (ID)

Abstract

Originally identified from a T-lymphoblastoid cell line (HUT 102) of a patient diagnosed with a cutaneous T-cell lymphoma, the human T-lymphotropic virus type I (HTLV-I) was the first described human retrovirus (1). In 1981, HTLV-I was established as the etiologic agent for adult T-cell leukemia (ATL) (2), a hematological malignancy first characterized in Japan (3). Since the initial description of ATL and the discovery of HTLV-I, the virus has been associated with an inflammatory, chronic, progressive neurologic disease known as HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) in addition to several other inflammatory diseases (4–14). Although an increasing number of human diseases have been linked to HTLV-I the vast majority of HTLV-I—infected individuals remain clinically asymptomatic.

Keywords

Proviral Load Spastic Paraparesis Tropical Spastic Paraparesis Cell Leukemia Virus Type Photropic Virus Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415–9.PubMedGoogle Scholar
  2. 2.
    Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78: 6476–80.PubMedGoogle Scholar
  3. 3.
    Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 481–92.PubMedGoogle Scholar
  4. 4.
    Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G. Antibodies to human Tlymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; ii:407–10.Google Scholar
  5. 5.
    Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity [letter]. Lancet 1986; i:1031–2.Google Scholar
  6. 6.
    Sasaki K, Morooka I, Inomata H, Kashio N, Akamine T, Osame M. Retinal vasculitis in human T-lymphotropic virus type I associated myelopathy. Br J Ophthalmol 1989; 73: 812–5.PubMedGoogle Scholar
  7. 7.
    Ohba N, Matsumoto M, Sameshima M, KabayamaY, Nakao K, Unoki K, et al. Ocular manifestations in patients infected with human T-lymphotropic virus type I. Jpn J Ophthalmol 1989; 33: 1–12.Google Scholar
  8. 8.
    Mochizuki M, Watanabe T, Yamaguchi K, Takatsuki K, Yoshimura K, Shirao M, et al. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res 1992; 83: 236–9.PubMedGoogle Scholar
  9. 9.
    Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I [letter]. Lancet 1989; 1: 441.PubMedGoogle Scholar
  10. 10.
    Sato K, Maruyama I, Maruyama Y, Kitajima I, Nakajima Y, Higaki M, et al. Arthritis in patients infected with human T lymphotropic virus type I. Clinical and immunopathologic features. Arthritis Rheum 1991; 34: 714–21.PubMedGoogle Scholar
  11. 11.
    Morgan OS, Rodgers-Johnson P, Mora C, Char G. HTLV-1 and polymyositis in Jamaica. Lancet 1989; ii:1184–7.Google Scholar
  12. 12.
    Sugimoto M, Nakashima H, Watanabe S, Uyama E, Tanaka F, Ando M, et al. T-lymphocyte alveolitis in HTLV-I-associated myelopathy [letter]. Lancet 1987; ií:1220.Google Scholar
  13. 13.
    Vernant JC, Buisson G, Magdeleine J, De Thore J, Jouannelle A, Neisson-Vernant C, Mon-plaisir N. T-lymphocyte alveolitis, tropical spastic paresis, and Sjogren syndrome [letter]. Lancet 1988; i:177.Google Scholar
  14. 14.
    Terada K, Katamine S, Eguchi K, Moriuchi R, Kita M, Shimada H, et al. Prevalence of serum and salivary antibodies to HTLV 1 in Sjogren’s syndrome [see comments]. Lancet 1994; 344: 1116–9.PubMedGoogle Scholar
  15. 15.
    Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982; 218: 571–3.PubMedGoogle Scholar
  16. 16.
    Coffin J. Retroviridae: the viruses and their replication. In: Fields BN, Knipe DM, et al. (eds). Virology, 3rd edit. Philadelphia: Lippincott-Raven, 1996, pp. 1767–847.Google Scholar
  17. 17.
    Gessain A, Gallo RC, Franchini G. Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. J Virol 1992; 66: 2288–95.PubMedGoogle Scholar
  18. 18.
    Ehrlich GD, Andrews J, Sherman MP, Greenberg SJ, Poiesz BJ. DNA sequence analysis of the gene encoding the HTLV-I p2 le transmembrane protein reveals inter-and intraisolate genetic heterogeneity. Virology 1992; 186: 619–27.PubMedGoogle Scholar
  19. 19.
    Koralnik I. Structure of HTLV-I. In: P Holsberg, Hafler D (eds). Human T-cell Lymphotropic Virus Type I. Chichester, England: John Wiley & Sons, 1996, pp. 79–112.Google Scholar
  20. 20.
    Brady J. Biology of HTLV-I: Host cell interactions. In: Hollsberg P, Hafler D (eds). Human T-Cell Lymphotropic Virus Type I. Chichester, England: John Wiley & Sons, 1996, pp. 79–112.Google Scholar
  21. 21.
    Inoue J, Seiki M, Taniguchi T, Tsuru S, Yoshida M. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. EMBO J 1986; 5: 2883–8.PubMedGoogle Scholar
  22. 22.
    Cross SL, Feinberg MB, Wolf JB, Holbrook NJ, Wong-Staal F, Leonard WJ. Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. Cell 1987; 49: 47–56.PubMedGoogle Scholar
  23. 23.
    Leung K, Nabel GJ. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature 1988; 333: 776–8.PubMedGoogle Scholar
  24. 24.
    Hoyos B, Ballard DW, Bohnlein E, Siekevitz M, Greene WC. Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science 1989; 244: 457–60.PubMedGoogle Scholar
  25. 25.
    Green JE, Begley CG, Wagner DK, Waldmann TA, Jay G. trans activation of granulocyte-macrophage colony-stimulating factor and the interleukin-2 receptor in transgenic mice carrying the human T-lymphotropic virus type 1 tax gene. Mol Cell Biol 1989; 9: 4731–7.PubMedGoogle Scholar
  26. 26.
    Curtiss VE, Smilde R, McGuire KL. Requirements for interleukin 2 promoter transactivation by the Tax protein of human T-cell leukemia virus type 1. Mol Cell Biol 1996; 16: 3567–75.PubMedGoogle Scholar
  27. 27.
    Azimi N, Brown K, Bamford RN, Tagaya Y, Siebenlist U, Waldmann TA. Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. Proc Natl Acad Sci USA 1998; 95: 2452–7.PubMedGoogle Scholar
  28. 28.
    Yamashita I, Katamine S, Moriuchi R, Nakamura Y, Miyamoto T, Eguchi K, Nagataki S. Trans-activation of the human interleukin-6 gene by human T-lymphotropic virus type 1 Tax protein. Blood 1994; 84: 1573–8.PubMedGoogle Scholar
  29. 29.
    Mori N, Ueda A, Ikeda S, Yamasaki Y, Yamada Y, Tomonaga M, et al. Human T-cell leukemia virus type I tax activates transcription of the human monocyte chemoattractant protein-1 gene through two nuclear factor-kappaB sites In Process Citation]. Cancer Res 2000; 60: 4939–45.PubMedGoogle Scholar
  30. 30.
    Fujii M, Sassone-Corsi P, Verma IM. c-fos promoter trans-activation by the taxi protein of human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1988; 85: 8526–30.PubMedGoogle Scholar
  31. 31.
    Nagata K, Ohtani K, Nakamura M, Sugamura K. Activation of endogenous c-fos proto-oncogene expression by human T-cell leukemia virus type I-encoded p40tax protein in the human T-cell line, Jurkat. J Virol 1989; 63: 3220–6.PubMedGoogle Scholar
  32. 32.
    Ratner L. Regulation of expression of the c-sis proto-oncogene. Nucleic Acids Res 1989; 17: 4101–15.PubMedGoogle Scholar
  33. 33.
    Watanabe T, Yamaguchi K, Takatsuki K, Osame M, Yoshida M. Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be transactivated by HTLV-1 tax gene. J Exp Med 1990; 172: 759–65.PubMedGoogle Scholar
  34. 34.
    Lemasson I, Robert-Hebmann V, Hamaia S, Duc Dodon M, Gazzolo L, Devaux C. Transrepression of lck gene expression by human T-cell leukemia virus type 1-encoded p40tax. J Virol 1997; 71: 1975–83.PubMedGoogle Scholar
  35. 35.
    Tanaka Y, Fukudome K, Hayashi M, Takagi S, Yoshie O. Induction of ICAM-1 and LFA-3 by Taxl of human T-cell leukemia virus type 1 and mechanism of downregulation of ICAM-1 or LFA-1 in adult-T-cell-leukemia cell lines. Int J Cancer 1995; 60: 554–61.PubMedGoogle Scholar
  36. 36.
    Jeang KT, Widen SG, Semmes Oit, Wilson SH. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990; 247: 1082–4.PubMedGoogle Scholar
  37. 37.
    Ejima E, Rosenblatt JD, Massari M, Quan E, Stephens D, Rosen CA, Prager D. Cell-type-specific transactivation of the parathyroid hormone-related protein gene promoter by the human T-cell leukemia virus type I (HTLV-I) tax and HTLV-II tax proteins. Blood 1993; 81: 1017–24.PubMedGoogle Scholar
  38. 38.
    Nimer SD, Gasson JC, Hu K, Smalberg I, Williams JL, Chen IS, Rosenblatt JD. Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. Oncogene 1989; 4: 671–6.PubMedGoogle Scholar
  39. 39.
    Seiki M, Inoue J, Hidaka M, Yoshida M. Two cis-acting elements responsible for posttranscriptional trans-regulation of gene expression of human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1988; 85: 7124–8.PubMedGoogle Scholar
  40. 40.
    Hidaka M, Inoue J, Yoshida M, Seiki M. Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins. EMBO J 1988; 7: 519–23.PubMedGoogle Scholar
  41. 41.
    Inoue J, Itoh M, Akizawa T, Toyoshima H, Yoshida M. HTLV 1 Rex protein accumulates unspliced RNA in the nucleus as well as in cytoplasm. Oncogene 1991; 6: 1753–7.PubMedGoogle Scholar
  42. 42.
    Cann AJ, Chen I. Human T-cell leukemia virus types I and II. In: BN Fields, DM Knipe, Howley P (eds). Fields Virology. Philadelphia: Lippincott-Raven, 1996, pp. 1849–50.Google Scholar
  43. 43.
    Kinoshita K, Hino S, Amagaski T, Ikeda S, Yamada Y, Suzuyama J, et al. Demonstration of adult T-cell leukemia virus antigen in milk from three sero-positive mothers. Gann 1984; 75: 103–5.PubMedGoogle Scholar
  44. 44.
    Nakano S, Ando Y, Ichijo M, Moriyama I, Saito S, Sugamura K, Hinuma Y. Search for possible routes of vertical and horizontal transmission of adult T-cell leukemia virus. Gann 1984; 75: 1044–5.PubMedGoogle Scholar
  45. 45.
    Ando Y, Nakano S, Saito K, Shimamoto I, Ichijo M, Toyama T, Hinuma Y. Transmission of adult T-cell leukemia retrovirus (HTLV-I) from mother to child: comparison of bottle-with breast-fed babies. Jpn J Cancer Res 1987; 78: 322–4.PubMedGoogle Scholar
  46. 46.
    Kouro A, Hayami M, Fujii H, et al. Vertical transmission of adult T-cell leukemia virus. Lancet 1983; i:240.Google Scholar
  47. 47.
    Hino S, Yamaguchi K, Katamine S, Sugiyama H, Amagasaki T, Kinoshita K, et al. Mother-tochild transmission of human T-cell leukemia virus type-I. Jpn J Cancer Res 1985; 76: 474–80.PubMedGoogle Scholar
  48. 48.
    Nyambi PN, Ville Y, Louwagie J, Bedjabaga I, Glowaczower E, Peeters M, et al. Mother-tochild transmission of human T-cell lymphotropic virus types I and II (HTLV-I/II) in Gabon: a prospective follow-up of 4 years. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 187–92.PubMedGoogle Scholar
  49. 49.
    Kajiyama W, Kashiwagi S, Ikematsu H, Hayashi J, Nomura H, Okochi K. Intrafamilial transmission of adult T cell leukemia virus. J Infect Dis 1986; 154: 851–7.PubMedGoogle Scholar
  50. 50.
    Brodine SK, Oldfield ECD, Corwin AL, Thomas RJ, Ryan AB, Holmberg J, et al. HTLV-I among U.S. Marines stationed in a hyperendemic area: evidence for female-to-male sexual transmission. J Acquir Immune Defic Syndr 1992; 5: 158–62.PubMedGoogle Scholar
  51. 51.
    Canavaggio M, Leckie G, Allain JP, Steaffens JW, Laurian Y, Brettler D, Lee H. The prevalence of antibody to HTLV-I/II in United States plasma donors and in United States and French hemophiliacs. Transfusion 1990; 30: 780–2.PubMedGoogle Scholar
  52. 52.
    Osame M, Janssen R, Kubota H, Nishitani H, Igata A, Nagataki S, et al. Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. Ann Neurol 1990; 28: 50–6.PubMedGoogle Scholar
  53. 53.
    Osame M, Izumo S, Igata A, Matsumoto M, Matsumoto T, Sonoda S, et al. Blood transfusion and HTLV-I associated myelopathy [letter]. Lancet 1986; 2: 104–5.PubMedGoogle Scholar
  54. 54.
    Donegan E, Busch MP, Galleshaw JA, Shaw GM, Mosley JW. Transfusion of blood components from a donor with human T-lymphotropic virus type II (HTLV-II) infection. The Transfusion Safety Study Group. Ann Intern Med 1990; 113: 555–6.PubMedGoogle Scholar
  55. 55.
    Sullivan MT, Williams AE, Fang CT, Grandinetti T, Poiesz BJ, Ehrlich GD. Transmission of human T-lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1988 ). The American Red Cross HTLV-UII Collaborative Study Group. Arch Intern Med 1991; 151: 2043–8.Google Scholar
  56. 56.
    Rios M, Khabbaz RF, Kaplan JE, Hall WW, Kessler D, Bianco C. Transmission of human T cell lymphotropic virus (HTLV) type II by transfusion of HTLV-I-screened blood products. J Infect Dis 1994; 170: 206–10.PubMedGoogle Scholar
  57. 57.
    Hjelle B, Cyrus S, Swenson SG. Evidence for sexual transmission of human T lymphotropic virus type II [letter]. Ann Intern Med 1992; 116: 90–1.PubMedGoogle Scholar
  58. 58.
    Vitek CR, Gracia FI, Giusti R, Fukuda K, Green DB, Castillo LC, et al. Evidence for sexual and mother-to-child transmission of human T lymphotropic virus type II among Guaymi Indians, Panama. J Infect Dis 1995; 171: 1022–6.PubMedGoogle Scholar
  59. 59.
    Hall WW, Ishak R, Zhu SW, Novoa P, Eiraku N, Takahashi H, et al. Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: S204–14.PubMedGoogle Scholar
  60. 60.
    Maloney EM, Armien B, Gracia F, Castillo L, Kruger H, Levin A, et al. Risk factors for human T cell lymphotropic virus type II infection among the Guaymi Indians of Panama. J Infect Dis 1999; 180: 876–9.PubMedGoogle Scholar
  61. 61.
    Ishak R, Harrington WJ Jr, Azevedo VN, Eiraku N, Ishak MO, Guerreiro JF, et al. Identification of human T cell lymphotropic virus type IIa infection in the Kayapo, an indigenous population of Brazil. AIDS Res Hum Retrovir 1995; 11: 813–21.PubMedGoogle Scholar
  62. 62.
    Yoshikura H, Nishida J, Yoshida M, Kitamura Y, Takaku F, Ikeda S. Isolation of HTLV derived from Japanese adult T-cell leukemia patients in human diploid fibroblast strain IMR90 and the biological characters of the infected cells. Int J Cancer 1984; 33: 745–9.PubMedGoogle Scholar
  63. 63.
    Ho DD, Rota TR, Hirsch MS. Infection of human endothelial cells by human T-lymphotropic virus type I. Proc Natl Acad Sci USA 1984; 81: 7588–90.PubMedGoogle Scholar
  64. 64.
    Koyanagi Y, Yamamoto N, Kobayashi N, Hirai K, Konishi H, Takeuchi K, et al. Characterization of human B-cell lines harbouring both adult T-cell leukaemia (ATL) virus and Epstein-Barr virus derived from ATL patients. J Gen Virol 1984; 65: 1781–9.PubMedGoogle Scholar
  65. 65.
    Sommerfelt MA, Williams BP, Clapham PR, Solomon E, Goodfellow PN, Weiss RA. Human T cell leukemia viruses use a receptor determined by human chromosome 17. Science 1988; 242: 1557–9.PubMedGoogle Scholar
  66. 66.
    Ijichi S, Ramundo MB, Takahashi H, Hall WW. In vivo cellular tropism of human T cell leukemia virus type II ( HTLV-II ). J Exp Med 1992; 176: 293–6.Google Scholar
  67. 67.
    Lal RB, Owen SM, Rudolph DL, Dawson C, Prince H. In vivo cellular tropism of human Tlymphotropic virus type II is not restricted to CD8+ cells. Virology 1995; 210: 441–7.PubMedGoogle Scholar
  68. 68.
    Inoue H, Yamaoka S, Imamura M, Hatanaka M. Suppression of the transformed phenotype in hybrids of human T-cell leukemia virus type I tax-transformed rat fibroblasts and normal human fibroblasts. Exp Cell Res 1994; 215: 68–74.PubMedGoogle Scholar
  69. 69.
    Hoshino H, Tanaka H, Shimotohno K, Miwa M, Nagai M, Shimoyama M, Sugimura T. Immortalization of peripheral blood lymphocytes of cats by human T-cell leukemia virus. Int J Cancer 1984; 34: 513–7.PubMedGoogle Scholar
  70. 70.
    Collins ND, Newbound GC, Ratner L, Lairmore MD. In vitro CD4+ lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotrophic virus type 1. J Virol 1996; 70: 7241–6.PubMedGoogle Scholar
  71. 71.
    Grassmann R, Berchtold S, Radant I, Alt M, Fleckenstein B, Sodroski JG, et al. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol 1992; 66: 4570–5.PubMedGoogle Scholar
  72. 72.
    Gessain A. Epidemiology of HTLV-I and Associated Diseases. In: Hollsberg P, Hafler D (eds). Human T-Cell Lymphotropic Virus Type I. Chichester, England: John Wiley & Sons, 1996, pp 33–64.Google Scholar
  73. 73.
    Blattner WA, Gallo RC. Epidemiology of HTLV-I and HTLV II infection. In: Takatsuki K (ed). Adult T-Cell Leukemia. Oxford: Oxford University Press, 1994, pp. 45–90.Google Scholar
  74. 74.
    Mueller N. The epidemiology of HTLV-I infection. Cancer Causes Control 1991; 2: 37–52.PubMedGoogle Scholar
  75. 75.
    Kaplan JE, Khabbaz RE The epidemiology of human T-lymphotropic virus types I and II. Med Virol 1993; 3: 137–48.Google Scholar
  76. 76.
    Levine PH, Blattner WA, Clark J, Tarone R, Maloney EM, Murphy EM, et al. Geographic distribution of HTLV-I and identification of a new high-risk population. Int J Cancer 1988; 42: 7–12.PubMedGoogle Scholar
  77. 77.
    Tajima K, Hinuma Y. Epidemiological features of adult T cell leukemia. In: Mathe G, Rizenstein P (eds). Pathophysiological Aspects of Cancer Epidemiology. Oxford: Pergamon Press, 1984, pp. 75–87.Google Scholar
  78. 78.
    Tajima K, Inoue H, Takezaki T, Itoh M, Itoh SI. Ethnoepidemiology of ATL in Japan with special reference to the Mongoloid dispersal. In: Takatsuki K (ed). Adult T-Cell Leukemia. Oxford: Oxford University Press, 1994, pp. 91–112.Google Scholar
  79. 79.
    Zucker-Franklin D, Pancake BA, Marmor M, Legler PM. Reexamination of human T cell lymphotropic virus (HTLV-I/II) prevalence. Proc Natl Acad Sci USA 1997; 94: 6403–7.PubMedGoogle Scholar
  80. 80.
    Zucker-Franklin D, Coutavas EE, Rush MG, Zouzias DC. Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes from patients with mycosis fungoides. Proc Natl Acad Sci USA 1991; 88: 7630–4.PubMedGoogle Scholar
  81. 81.
    Goubau P, Liu HF, De Lange GG, Vandamme AM, Desmyter J. HTLV-II seroprevalence in pygmies across Africa since 1970. AIDS Res Hum Retrovir 1993; 9: 709–13.PubMedGoogle Scholar
  82. 82.
    Froment A, Delporte E, Dazza MC, Larouze B. HTLV-II infection in Guinea West Africa. AIDS Res Hum Retrovir 1993; 9: 707.PubMedGoogle Scholar
  83. 83.
    Gessain A, Fretz C, Koulibaly M, Boudret ML, Bah A, Raphael M, et al. Evidence of HTLV-II infection in Guinea, West Africa [letter] [see comments]. J Acquir Immune Defic Syndr 1993; 6: 324–5.PubMedGoogle Scholar
  84. 84.
    Igarashi T, Yamashita M, Miura T, Osei-Kwasi M, Aysi NK, Shiraki H, et al. Isolation and genomic analysis of human T lymphotropic virus type II from Ghana. AIDS Res Hum Retrovir 1993; 9: 1039–42.PubMedGoogle Scholar
  85. 85.
    Bonis J, Verdier M, Dumas M, Denis F. Low human T cell leukemia virus type II seroprevalence in Africa [letter]. J Infect Dis 1994; 169: 225–7.PubMedGoogle Scholar
  86. 86.
    Vallejo A, Benito A, Varela JM, Casado C, Roche J, Alvar J, Garcia-Saiz A. Human T-cell leukaemia virus-UII infection in Equatorial Guinea [letter]. AIDS 1994; 8: 1501–3.PubMedGoogle Scholar
  87. 87.
    Buckner C, Roberts CR, Foung SK, Lipka J, Reyes GR, Hadlock K, et al. Immune responsiveness to the immunodominant recombinant envelope epitopes of human T lymphotropic virus types I and II in diverse geographic populations. J Infect Dis 1992; 166: 1160–3.PubMedGoogle Scholar
  88. 88.
    Hjelle B, Scalf R, Swenson S. High frequency of human T-cell leukemia-lymphoma virus type II infection in New Mexico blood donors: determination by sequence-specific oligonucleotide hybridization. Blood 1990; 76: 450–4.PubMedGoogle Scholar
  89. 89.
    Hjelle B, Mills R, Swenson S, Mertz G, Key C, Allen S. Incidence of hairy cell leukemia, mycosis fungoides, and chronic lymphocytic leukemia in first known HTLV-II-endemic population. J Infect Dis 1991; 163: 435–40.PubMedGoogle Scholar
  90. 90.
    Hjelle B. Human T-cell leukemia/lymphoma viruses. Life cycle, pathogenicity, epidemiology, and diagnosis. Arch Pathol Lab Med 1991; 115: 440–50.PubMedGoogle Scholar
  91. 91.
    Levine PH, Jacobson S, Elliott R, Cavallero A, Colclough G, Dorry C, et al. HTLV-II infection in Florida Indians. AIDS Res Hum Retrovir 1993; 9: 123–7.PubMedGoogle Scholar
  92. 92.
    Lairmore MD, Jacobson S, Gracia F, De BK, Castillo L, Larreategui M, et al. Isolation of human T-cell lymphotropic virus type 2 from Guaymi Indians in Panama. Proc Natl Acad Sci USA 1990; 87: 8840–4.PubMedGoogle Scholar
  93. 93.
    Duenas-Barajas E, Bernal JE, Vaught DR, Briceno I, Duran C, Yanagihara R, Gajdusek DC. Coexistence of human T-lymphotropic virus types I and II among the Wayuu Indians from the Guajira Region of Colombia. AIDS Res Hum Retrovir 1992; 8: 1851–5.PubMedGoogle Scholar
  94. 94.
    Fujiyama C, Fujiyoshi T, Miura T, Yashiki S, Matsumoto D, Zaninovic V, et al. A new endemic focus of human T lymphotropic virus type II carriers among Orinoco natives in Colombia [letter]. J Infect Dis 1993; 168: 1075–7.PubMedGoogle Scholar
  95. 95.
    Duenas-Barajas E, Bernal JE, Vaught DR, Nerurkar VR, Sarmiento P, Yanagihara R, Gajdusek DC. Human retroviruses in Amerindians of Colombia: high prevalence of human T cell lymphotropic virus type II infection among the Tunebo Indians. Am J Trop Med Hyg 1993; 49: 657–63.PubMedGoogle Scholar
  96. 96.
    Black FL, Biggar RJ, Neel JV, Maloney EM, Waters DJ. Endemic transmission of HTLV type II among Kayapo Indians of Brazil. AIDS Res Hum Retrovir 1994; 10: 1165–71.PubMedGoogle Scholar
  97. 97.
    Maloney EM, Biggar RJ, Neel JV, Taylor ME, Hahn BH, Shaw GM, Blattner WA. Endemic human T cell lymphotropic virus type II infection among isolated Brazilian Amerindians. J Infect Dis 1992; 166: 100–7.PubMedGoogle Scholar
  98. 98.
    Ferrer JF, Del Pino N, Esteban E, Sherman MP, Dube S, Dube DK, et al. High rate of infection with the human T-cell leukemia retrovirus type II in four Indian populations of Argentina. Virology 1993; 197: 576–84.PubMedGoogle Scholar
  99. 99.
    Hjelle B, Khabbaz RF, Conway GA, North C, Green D, Kaplan JE. Prevalence of human T cell lymphotropic virus type II in American Indian populations of the southwestern United States. Am J Trop Med Hyg 1994; 51: 11–5.PubMedGoogle Scholar
  100. 100.
    Hall WW, Takahashi H, Liu C, Kaplan MH, Scheewind O, Ijichi S, et al. Multiple isolates and characteristics of human T-cell leukemia virus type II. J Virol 1992; 66: 2456–63.PubMedGoogle Scholar
  101. 101.
    Hjelle B, Zhu SW, Takahashi H, Ijichi S, Hall WW. Endemic human T cell leukemia virus type II infection in southwestern US Indians involves two prototype variants of virus. J Infect Dis 1993; 168: 737–40.PubMedGoogle Scholar
  102. 102.
    Khabbaz RF, Onorato IM, Cannon RO, Hartley TM, Roberts B, Hosein B, Kaplan JE. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992; 326: 375–80.PubMedGoogle Scholar
  103. 103.
    Hall WW, Kubo T, Ijichi S, Takahashi H, Zhu SW. Human T-cell leukemia/lymphoma virus type II (HTLV-II): emergence of an important newly recognised pathogen. Semin Virol 1994; 5: 165–78.Google Scholar
  104. 104.
    Dube DK, Sherman MP, Saksena NK, Bryz-Gornia V, Mendelson J, Love J, et al. Genetic heterogeneity in human T-cell leukemia/lymphoma virus type II. J Virol 1993; 67: 1175–84.PubMedGoogle Scholar
  105. 105.
    Pardi D, Switzer WM, Hadlock KG, Kaplan JE, Lal RB, Folks TM. Complete nucleotide sequence of an Amerindian human T-cell lymphotropic virus type II (HTLV-II) isolate: identification of a variant HTLV-II subtype b from a Guaymi Indian. J Virol 1993; 67: 4659–64.PubMedGoogle Scholar
  106. 106.
    Pardi D, Kaplan JE, Coligan JE, Folks TM, Lal RB. Identification and characterization of an extended Tax protein in human T-cell lymphotropic virus type II subtype b isolates. J Virol 1993; 67: 7663–7.PubMedGoogle Scholar
  107. 107.
    Eiraku N, Novoa P, da Costa Ferreira M, Monken C, Ishak R, da Costa Ferreira O, et al. Identification and characterization of a new and distinct molecular subtype of human T-cell lymphotropic virus type 2. J Virol 1996; 70: 1481–92.PubMedGoogle Scholar
  108. 108.
    Lal RB, Rudolph DL, Coligan JE, Brodine SK, Roberts CR. Failure to detect evidence of human T-lymphotropic virus (HTLV) type I and type II in blood donors with isolated gag antibodies to HTLV-I/II. Blood 1992; 80: 544–50.PubMedGoogle Scholar
  109. 109.
    Lal RB, Rudolph D, Alpers MP, Sulzer AJ, Shi YP, Lal AA. Immunologic cross-reactivity between structural proteins of human T-cell lymphotropic virus type I and the blood stage of Plasmodium falciparum. Clin Diagn Lab Immunol 1994; 1: 5–10.PubMedGoogle Scholar
  110. 110.
    Hayes CG, Burans JP, Oberst RB. Antibodies to human T lymphotropic virus type I in a population from the Philippines: evidence for cross-reactivity with Plasmodium falciparum. J Infect Dis 1991; 163: 257–62.PubMedGoogle Scholar
  111. 111.
    Mauclere P, Le Hesran JY, Mahieux R, Salla R, Mfoupouendoun J, Abada ET, et al. Demographic, ethnic, and geographic differences between human T cell lymphotropic virus (HTLV) type I-seropositive carriers and persons with HTLV-I Gag-indeterminate Western blots in Central Africa. J Infect Dis 1997; 176: 505–9.PubMedGoogle Scholar
  112. 112.
    Busch MP, Switzer WM, Murphy EL, Thomson R, Heneine W. Absence of evidence of infection with divergent primate T-lymphotropic viruses in United States blood donors who have seroindeterminate HTLV test results. Transfusion 2000; 40: 443–9.PubMedGoogle Scholar
  113. 113.
    Soldan SS, Graf MD, Waziri A, Flerlage AN, Robinson SM, Kawanishi T, et al. HTLV-I/1I seroindeterminate Western blot reactivity in a cohort of patients with neurological disease. J Infect Dis 1999; 180: 685–94.PubMedGoogle Scholar
  114. 114.
    Waziri A, Soldan SS, Graf MD, Nagle J, Jacobson S. Characterization and sequencing of prototypic human T-lymphotropic virus type I (HTLV-1) from an HTLV-1/2 seroindeterminate patient [In Process Citation]. J Virol 2000; 74: 2178–85.PubMedGoogle Scholar
  115. 115.
    Cesaire R, Bera O, Maier H, Lezin A, Martial J, Ouka M, et al. Seroindeterminate patterns and seroconversions to human T-lymphotropic virus type I positivity in blood donors from Martinique, French West Indies. Transfusion 1999; 39: 1145–9.PubMedGoogle Scholar
  116. 116.
    Group TaBCMS. The third nation-wide study on adult-T-cell leukemia/lymphoma (ATL) in Japan: characteristic patterns of HLA antigen and HTLV-I infection in ATL patients and their relatives. Int J Cancer 1988; 41: 505–12.Google Scholar
  117. 117.
    Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geopraphical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer 1990; 45: 237–43.PubMedGoogle Scholar
  118. 118.
    Takatsuki K, Yamaguchi K, Matsuoka M. Adult T-Cell Leukemia. Human T-Cell Lymphotropic Virus Type I. Chichester, England: John Wiley & Sons, 1996, pp. 219–46.Google Scholar
  119. 119.
    Takatsuki K, Yamaguchi K, Matsuoka M. ATL and HTLV-I related diseases. In: Takatsuki K (ed). Adult T-Cell Leukaemia. Oxford: Oxford University Press, 1994, pp. 1–27.Google Scholar
  120. 120.
    Kondo T, Nonaka H, Miyamoto N. Epidemiology of ATLL and preceding stage in a cluster area. Recent Adv Res 1987; 24: 156–61.Google Scholar
  121. 121.
    Kawano F, Yamaguchi K, Nishimura H, Tsuda H, Takatsuki K. Variation in the clinical courses of adult T-cell leukemia. Cancer 1985; 55: 851–6.PubMedGoogle Scholar
  122. 122.
    Yamaguchi K, Nishimura H, Kohrogi H, Jono M, Miyamoto Y, Takatsuki K. A proposal for smoldering adult T-cell leukemia: a clinicopathologic study of five cases. Blood 1983; 62: 758–66.PubMedGoogle Scholar
  123. 123.
    Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol 1991; 79: 428–37.Google Scholar
  124. 124.
    Blayney DW, Jaffe ES, Blattner WA, Cossman J, Robert-Guroff M, Longo DL, et al. The human T-cell leukemia/lymphoma virus associated with American adult T-cell leukemia/lymphoma. Blood 1983; 62: 401–5.PubMedGoogle Scholar
  125. 125.
    Bunn PA Jr, Schechter GP, Jaffe E, Blayney D, Young RC, Matthews MJ, et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 1983; 309: 257–64.PubMedGoogle Scholar
  126. 126.
    Hoshino H, Esumi H, Miwa M, Shimoyama M, Minato K, Tobinai K, et al. Establishment and characterization of 10 cell lines derived from patients with adult T-cell leukemia. Proc Natl Acad Sci USA 1983; 80: 6061–5.PubMedGoogle Scholar
  127. 127.
    Roman GC, Osame M. Identity of HTLV-I-associated tropical spastic paraparesis and HTLV-Iassociated myelopathy [letter]. Lancet 1988; i:651.Google Scholar
  128. 128.
    Osame M. Reveiw of WHO kagoshima meeting and diagnostic guidelines for HAM/TSP. In: Blattner W (ed). Human Retrovirology HTLV. New York: Raven Press, 1990, pp. 191–7.Google Scholar
  129. 129.
    Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, et al. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells. Ann Neurol 1987; 21: 117–22.PubMedGoogle Scholar
  130. 130.
    Osame M, Igata A, Matsumoto M, Kohka M, Usuku K, Izumo S. HTLV-I associated myelopathy (HAM), treatment trials, retrospective survey and clinical and laboratory findings. Hematol Rev 1990; 3: 271–84.Google Scholar
  131. 131.
    Osame M, McArthur JC. Neurologic manifestations of infection with human T cell lymphotropic virus type I. In: Asburr AK, McKhann GM, McDonald WI (eds). Disease of the Nervous System: Clinical Neurobiology. Philadelphia: WB Saunders, 1990, pp. 1331–9.Google Scholar
  132. 132.
    McFarlin DE, Blattner WA. Non-AIDS retroviral infections in humans. Annu Rev Med 1991; 42: 97–105.PubMedGoogle Scholar
  133. 133.
    Hollsberg P, Hafler D. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N Engl J Med 1993; 328: 1173–82.PubMedGoogle Scholar
  134. 134.
    Ceroni M, Piccardo P, Rodgers-Johnson P, Mora C, Asher DM, Gajdusek DC, Gibbs CJ, Jr. Intrathecal synthesis of IgG antibodies to HTLV-I supports an etiological role for HTLV-I in tropical spastic paraparesis. Ann Neurol 1988; 23: S188–91.PubMedGoogle Scholar
  135. 135.
    Link H, Cruz M, Gessain A, Gout O, de The G, Kam-Hansen S. Chronic progressive myelopathy associated with HTLV-I: oligoclonal IgG and anti-HTLV-I IgG antibodies in cerebrospinal fluid and serum. Neurology 1989; 39: 1566–72.PubMedGoogle Scholar
  136. 136.
    Nomoto M, Utatsu Y, Soejima Y, Osame M. Neopterin in cerebrospinal fluid: a useful marker for diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis. Neurology 1991; 41: 457.PubMedGoogle Scholar
  137. 137.
    Mattson DH, McFarlin DE, Mora C, Zaninovic V. Central-nervous-system lesions detected by magnetic resonance imaging in an HTLV-I antibody positive symptomless individual [letter]. Lancet 1987; íi:49.Google Scholar
  138. 138.
    Cruickshank JK, Rudge P, Dalgleish AG, Newton M, McLean BN, Barnard RO, et al. Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain 1989; 112: 1057–90.PubMedGoogle Scholar
  139. 139.
    Nakagawa M, Izumo S, Ijichi S, Kubota H, Arimura K, Kawabata M, Osame M. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1995; 1: 50–61.PubMedGoogle Scholar
  140. 140.
    Arimura K, Rosales R, Osame M, Igata A. Clinical electrophysiologic studies of HTLV-I-associated myelopathy. Arch Neurol 1987; 44: 609–12.PubMedGoogle Scholar
  141. 141.
    Ludolph AC, Hugon J, Roman GC, Spencer PS, Schoenberg BS. A clinical neurophysiologic study of tropical spastic paraparesis. Muscle Nerve 1988; 11: 392–7.PubMedGoogle Scholar
  142. 142.
    Arimura K, Arimura M, Yonenaga Y, Rosales R, Osame M. Clinical electrophoysiologic findings in patients with HTLV I associated myelopathy. In: Roman GC, Vernant JC, Osame M (eds). HTLV-I and the Nervous System. New York: Alan R Liss, 1989, pp. 240–50.Google Scholar
  143. 143.
    Arimura K, Arimura Y, Moritoyo H, Tokimura Y, Takenaga S, Sonoda Y, et al. How helpful is thoracic paraspinal EMG in HAM/TSP? Muscle Nerve 1995; 18: 248–50.PubMedGoogle Scholar
  144. 144.
    Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y, et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990; 3: 1096–101.PubMedGoogle Scholar
  145. 145.
    LaGrenade L, Hanchard B, Fletcher V, Carnston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTLV-I infection [see comments]. Lancet 1990; 336: 1345–7.PubMedGoogle Scholar
  146. 146.
    Kanazawa H, Ijichi S, Eiraku N, Igakura T, Higuchi I, Nakagawa M, Kuriyama M, Tanaka S, Osame M. Behçet’s disease and Sjogren syndrome in a patient with HTLV-I-associated myelopathy [letter]. J Neurol Sci 1993; 119: 121–2.PubMedGoogle Scholar
  147. 147.
    Igakura T, Kawahigashi Y, Kanazawa H, Nakagawa M, Osame M. HTLV-I and Behcet’s disease [letter]. J Rheumatol 1993; 20: 2175–6.PubMedGoogle Scholar
  148. 148.
    Yoshida Y, Sakamoto Y, Yoshimine A, Maruyama Y, Ikegami N, Inose M, et al. Three cases of juvenile onset HTLV-I-associated myelopathy with pseudohypoparathyroidism. J Neurol Sci 1993; 118: 145–9.PubMedGoogle Scholar
  149. 149.
    Takayanagui OM, Moura LS, Petean FC, Biscaro TA, Covas DT, Osame M. Human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis and systemic lupus erythematosus. Neurology 1997; 48: 1469–70.PubMedGoogle Scholar
  150. 150.
    Watanabe T, Ono A, Mochizuki M. Analysis of the infiltrating cells of HTLV-I uveitis. AIDS Res Hum Retrovir 1994; 10: 444.Google Scholar
  151. 151.
    Mochizuki M, Ono A, Ikeda E, Hikita N, Watanabe T, Yamaguchi K, et al. HTLV-I uveitis. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: S50–6.Google Scholar
  152. 152.
    Hall WW, Liu CR, Schneewind 0, Takahashi H, Kaplan MH, Roupe G, Vahlne A. Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides [see cornments]. Science 1991; 253: 317–20.PubMedGoogle Scholar
  153. 153.
    Nishimura M, Mingioli E, McFarlin DE, Jacobson S. Demonstration of human T-cell lymphotropic virus type I (HTLV-I) from an HTLV-I seronegative south Indian patient with chronic, progressive spastic paraparesis. Ann Neurol 1993; 34: 867–70.PubMedGoogle Scholar
  154. 154.
    Rosenblatt JD, Giorgi JV, Golde DW, Ezra JB, Wu A, Winberg CD, et al. Integrated human T-cell leukemia virus II genome in CD8+ T cells from a patient with “atypical” hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders. Blood 1988; 71: 363–9.PubMedGoogle Scholar
  155. 155.
    Kaplan MH, Hall WW, Susin M, Pahwa S, Salahuddin SZ, Heilman C, et al. Syndrome of severe skin disease, eosinophilia, and dermatopathic lymphadenopathy in patients with HTLV-II complicating human immunodeficiency virus infection. Am J Med 1991; 91: 300–9.PubMedGoogle Scholar
  156. 156.
    Bryz-Gornia V, Bushunow P, Amin R. Cutaneous T-cell lymphoma in a patient with HTLV-II and HIV. AIDS Res Hum Retrovir 1994; 10: 474.Google Scholar
  157. 157.
    Modahl LE, Young KC, Varney KF, Khayam-Bashi H, Murphy EL. Are HTLV-II-seropositive injection drug users at increased risk of bacterial pneumonia, abscess, and lymphadenopathy? J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 169–75.PubMedGoogle Scholar
  158. 158.
    Berger JR, Svenningsson A, Raffanti S, Resnick L. Tropical spastic paraparesis-like illness occurring in a patient dually infected with HIV-1 and HTLV-II. Neurology 1991; 41: 85–7.PubMedGoogle Scholar
  159. 159.
    Harrington WJ Jr, Sheremata W, Hjelle B, Dube DK, Bradshaw P, Foung SK, et al. Spastic ataxia associated with human T-cell lymphotropic virus type II infection. Ann Neurol 1993; 33: 411–4.PubMedGoogle Scholar
  160. 160.
    Sheremata WA, Harrington WJ Jr, Bradshaw PA, Foung SK, Raffanti SP, Berger JR, et al. Association of `(tropical) ataxic neuropathy’ with HTLV-II. Virus Res 1993; 29: 71–7.PubMedGoogle Scholar
  161. 161.
    Jacobson S, Lehky T, Nishimura M, Robinson S, McFarlin DE, Dhib-Jalbut S. Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann Neurol 1993; 33: 392–6.PubMedGoogle Scholar
  162. 162.
    Hjelle B, Appenzeller O, Mills R, Alexander S, Torrez-Martinez N, Jahnke R, Ross G. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 1992; 339: 645–6.PubMedGoogle Scholar
  163. 163.
    Zehender G, Meroni L, Varchetta S, De Maddalena C, Cavalli B, Gianotto M, et al. Human Tlymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathy. J Virol 1998; 72: 7664–8.PubMedGoogle Scholar
  164. 164.
    Lefrere JJ, Courouce AM, Mariotti M, Wattel E, Prou O, Bouchardeau F, Lambin P. Rapid progression to AIDS in dual HIV-1/HTLV I infection [letter]. Lancet 1990; 336: 509.PubMedGoogle Scholar
  165. 165.
    Visconti A, Visconti L, Bellocco R, Binkin N, Colucci G, Vernocchi L, et al. HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. J Acquir Immune Defic Syndr 1993; 6: 1228–37.PubMedGoogle Scholar
  166. 166.
    Usuku K, Sonoda S, Osame M, Yashiki S, Takahashi K, Matsumoto M, et al. HLA haplotypelinked high immune responsiveness against HTLV-I in HTLV I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma. Ann Neurol 1988; 23: S143–50.PubMedGoogle Scholar
  167. 167.
    Sonoda S, Fujiyoshi T, Yashiki S. Immunogenetics of HTLV I/II and associated diseases. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: S119–23.PubMedGoogle Scholar
  168. 168.
    Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 1999; 96: 3848–53.PubMedGoogle Scholar
  169. 169.
    Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000; 55: 140–8.PubMedGoogle Scholar
  170. 170.
    Nagai M, Usuku K, Matsumoto w, Kodama D, Takenouchi N, Moritoyo T, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4: 586–93.PubMedGoogle Scholar
  171. 171.
    Gessain A. Virological aspects of tropical spastic paraparesis/HTLV-I associated myelopathy and HTLV-I infection [see comments]. J Neurovirol 1996; 2: 299–306.PubMedGoogle Scholar
  172. 172.
    Kubota R, Fujiyoshi T, Izumo S, Yashiki S, Maruyama I, Osame M, Sonoda S. Fluctuation of HTLV-I proviral DNA in peripheral blood mononuclear cells of HTLV-I-associated myelopathy. J Neuroimmunol 1993; 42: 147–54.PubMedGoogle Scholar
  173. 173.
    Kira J, Koyanagi Y, Yamada T, Itoyama Y, Goto I, Yamamoto N, et al. Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study [published erratum appears in Ann Neurol 1991 Apr;29(4):363]. Ann Neurol 1991; 29: 194–201.Google Scholar
  174. 174.
    Hanon E, Hall S, Taylor GP, Saito M, Davis R, Tanaka Y, et al. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000; 95: 1386–92.PubMedGoogle Scholar
  175. 175.
    Furukawa Y, Osame M, Kubota R, Tara M, Yoshida M. Human T-cell leukemia virus type-1 (HTLV 1) Tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic paraparesis patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells. Blood 1995; 85: 1865–70.PubMedGoogle Scholar
  176. 176.
    Levin MC, Jacobson S. HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP): a chronic progressive neurologic disease associated with immunologically mediated damage to the central nervous system. J Neurovirol 1997; 3: 126–40.PubMedGoogle Scholar
  177. 177.
    Piccardo P, Ceroni M, Rodgers-Johnson P, Mora C, Asher DM, Char G, et al. Pathological and immunological observations on tropical spastic paraparesis in patients from Jamaica. Ann Neurol 1988; 23: 5156–60.Google Scholar
  178. 178.
    Izumo S, Usuku K, Osame M, Machigashira K, Johnson M, Hakagawa M. The neuropathology of HTLV-I associated myelopathy in Japan: report of an autopsy case and review of the literature. In: Roman GC, Vernant JC, Osame M (eds). HTLV-I and the Nervous System. New York: Alan R Liss, 1989, pp. 261–7.Google Scholar
  179. 179.
    Moore GR, Traugott U, Scheinberg LC, Raine CS. Tropical spastic paraparesis: a model of virus-induced, cytotoxic T-cell-mediated demyelination? Ann Neurol 1989; 26: 523–30.PubMedGoogle Scholar
  180. 180.
    Yoshioka A, Hirose G, Ueda Y, Nishimura Y, Sakai K. Neuropathological studies of the spinal cord in early stage HTLV-I-associated myelopathy (HAM). J Neurol Neurosurg Psychiatry 1993; 56: 1004–7.PubMedGoogle Scholar
  181. 181.
    Akizuki S, Yoshida S, Setoguchi M, et al. The neuropathology of human T cell lymphotropic virus type I-associated myelopathy. In: Roman GC, Vernant JC, Osame M, et al. (eds). HTLV-I and the Nervous System. New York: Alan R Liss, 1989, pp. 253–60.Google Scholar
  182. 182.
    Wu E, Dickson DW, Jacobson S, Raine CS. Neuroaxonal dystrophy in HTLV-1-associated myelopathy/tropical spastic paraparesis: neuropathologic and neuroimmunologic correlations. Acta Neuropathol 1993; 86: 224–35.PubMedGoogle Scholar
  183. 183.
    Umehara F, Nakamura A, Izumo S, Kubota R, Ijichi S, Kashio N, et al. Apoptosis of T lymphocytes in the spinal cord lesions in HTLV-I-associated myelopathy: a possible mechanism to control viral infection in the central nervous system. J Neuropathol Exp Neurol 1994; 53: 617–24.PubMedGoogle Scholar
  184. 184.
    Umehara F, Izumo S, Nakagawa M, Ronquillo AT, Takahashi K, Matsumuro K, et al. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 1993; 52: 424–30.PubMedGoogle Scholar
  185. 185.
    Umehara F, Izumo S, Takeya M, Takahashi K, Sato E, Osame M. Expression of adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) in the spinal cord lesions in HTLV-Iassociated myelopathy. Acta Neuropathol 1996; 91: 343–50.PubMedGoogle Scholar
  186. 186.
    Iwasaki Y. Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP). J Neurol Sci 1990; 96: 103–23.PubMedGoogle Scholar
  187. 187.
    Kira J, Itoyama Y, Koyanagi Y, Tateishi J, Kishikawa M, Akizuki S, et al. Presence of HTLV-I proviral DNA in central nervous system of patients with HTLV-I-associated myelopathy. Ann Neurol 1992; 31: 39–45.PubMedGoogle Scholar
  188. 188.
    Ohara Y, Iwasaki Y, Izumo S, Kobayashi I, Yoshioka A. Search for human T-cell leukemia virus type I (HTLV-I) proviral sequences by polymerase chain reaction in the central nervous system tissue of HTLV-I-associated myelopathy. Arch Virol 1992; 124: 31–43.PubMedGoogle Scholar
  189. 189.
    Jacobson S, Zaninovic V, Mora C, Rodgers-Johnson P, Sheremata WA, Gibbs CJ, Jr, et al. Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis. Ann Neurol 1988; 23: S196–200.PubMedGoogle Scholar
  190. 190.
    Jacobson S, McFarlin DE, Robinson S, Voskuhl R, Martin R, Brewah A, et al. HTLV-I-specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I-associated neurological disease. Ann Neurol 1992; 32: 651–7.PubMedGoogle Scholar
  191. 191.
    Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990; 348: 245–8.PubMedGoogle Scholar
  192. 192.
    Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T, Jacobson S. High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. J Exp Med 1993; 177: 1567–73.PubMedGoogle Scholar
  193. 193.
    Nagasato K, Nakamura T, Shirabe S, Shibayama K, Ohishi K, Ichinose K, et al. Presence of serum anti-human T-lymphotropic virus type I (HTLV-I) IgM antibodies means persistent active replication of HTLV I in HTLV-I-associated myelopathy. J Neurol Sci 1991; 103: 203–8.PubMedGoogle Scholar
  194. 194.
    Matsui M, Nagumo F, Tadano J, Kuroda Y. Characterization of humoral and cellular immunity in the central nervous system of HAM/TSP. J Neurol Sci 1995; 130: 183–9.PubMedGoogle Scholar
  195. 195.
    Kuroda Y, Matsui M. Cerebrospinal fluid interferon-gamma is increased in HTLV-I-associated myelopathy. J Neuroimmunol 1993; 42: 223–6.PubMedGoogle Scholar
  196. 196.
    Nakamura S, Nagano I, Yoshioka M, Shimazaki S, Onodera J, Kogure K. Detection of tumor necrosis factor-alpha-positive cells in cerebrospinal fluid of patients with HTLV-I-associated myelopathy. J Neuroimmunol 1993; 42: 127–30.PubMedGoogle Scholar
  197. 197.
    Nishimoto N, Yoshizaki K, Eiraku N, Machigashira K, Tagoh H, Ogata A, et al. Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurol Sci 1990; 97: 183–93.PubMedGoogle Scholar
  198. 198.
    Tendler CL, Greenberg SJ, Blattner WA, Manns A, Murphy E, Fleisher T, et al. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci USA 1990; 87: 5218–22.PubMedGoogle Scholar
  199. 199.
    Tendler CL, Greenberg SJ, Burton JD, Danielpour D, Kim SJ, Blattner WA, et al. Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis. J Cell Biochem 1991; 46: 302–11.PubMedGoogle Scholar
  200. 200.
    Matsuda M, Tsukada N, Miyagi K, Yanagisawa N. Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type- 1-associated myelopathy. J Neuroimmunol 1995; 59: 35–40.PubMedGoogle Scholar
  201. 201.
    Saarloos MN, Koenig RE, Spear GT. Elevated levels of iC3b and C4d, but not Bb, complement fragments from plasma of persons infected with human T cell leukemia virus (HTLV) with HTLV I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 1995; 172: 1095–7.PubMedGoogle Scholar
  202. 202.
    Morimoto C, Matsuyama T, Oshige C, Tanaka H, Hercend T, Reinherz EL, Schlossman SF. Functional and phenotypic studies of Japanese adult T cell leukemia cells. J Clin Invest 1985; 75: 836–43.PubMedGoogle Scholar
  203. 203.
    Kitajima I, Osame M, Izumo S, Igata A. Immunological studies of HTLV-I associated myelopathy. Autoimmunity 1988; 1: 125–31.PubMedGoogle Scholar
  204. 204.
    Yasuda K, Sei Y, Yokoyama MM, Tanaka K, Hara A. Healthy HTLV-I carriers in Japan: the haematological and immunological characteristics. Br J Haematol 1986; 64: 195–203.PubMedGoogle Scholar
  205. 205.
    Kramer A, Jacobson S, Reuben JF, Murphy EL, Wiktor SZ, Cranston B, et al. Spontaneous lymphocyte proliferation in symptom-free HTLV-I positive Jamaicans [letter]. Lancet 1989; 2: 923–4.PubMedGoogle Scholar
  206. 206.
    Wiktor SZ, Jacobson S, Weiss SH, Shaw GM, Reuben JS, Shorty VJ, et al. Spontaneous lymphocyte proliferation in HTLV-II infection. Lancet 1991; 337: 327–8.PubMedGoogle Scholar
  207. 207.
    Ijichi S, Machigashira K, Nagai M, Osame M, Osame M, Hall WW. Late phase spontaneous proliferation of cultured peripheral blood lymphocytes associated with HTLV-I infection: involvement of cellular responses against the infected cells. Jpn J Trop Med Hyg 1996; 24: 143–9.Google Scholar
  208. 208.
    Eiraku N, Ijichi S, Yashiki S, Osame M, Sonoda S. Cell surface phenotype of in vitro proliferating lymphocytes in HTLV-I-associated myelopathy (HAM/TSP). J Neuroimmunol 1992; 37: 223–8.PubMedGoogle Scholar
  209. 209.
    Machigashira K, Ijichi S, Nagai M, Yamano Y, Hall WW, Osame M. In vitro virus propagation and high cellular responsiveness to the infected cells in patients with HTLV-I-associated myelopathy ( HAM/TSP ). J Neurol Sci 1997; 149: 141–5.Google Scholar
  210. 210.
    Itoyama Y, Minato S, Kira J, Goto I, Sato H, Okochi K, Yamamoto N. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology 1988; 38: 1302–7.PubMedGoogle Scholar
  211. 211.
    Ijichi N, Eiraku N, Osame M, et al. Hypothetical pathogenesis of HAM/TSP: occurrence of proliferative response of lymphocytes in the central nervous system. In: Roman GC, Vernant JC, Osame M, (eds). HTLV-I and the Nervous System. New York: Alan R Liss, 1989, pp. 242–59.Google Scholar
  212. 212.
    Kannagi M, Matsushita S, Shida H, Harada S. Cytotoxic T cell response and expression of the target antigen in HTLV-I infection. Leukemia 1994; 8 Suppl 1: 554–9.Google Scholar
  213. 213.
    Jacobson S, McFarlin D, Robinson S. Demonstration of HTLV-I specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I associated neurologic disease. Ann Neurol 1992; 32: 651–7.PubMedGoogle Scholar
  214. 214.
    Koenig S, Woods RM, Brewah YA, Newell AJ, Jones GM, Boone E, et al. Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease. J Immunol 1993; 151: 3874–83.PubMedGoogle Scholar
  215. 215.
    Parker CE, Daenke S, Nightingale S, Bangham CR. Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic para-paresis. Virology 1992; 188: 628–36.PubMedGoogle Scholar
  216. 216.
    Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima G, et al. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV I-infected cells. Int Immunol 1991; 3: 761–7.PubMedGoogle Scholar
  217. 217.
    Shida H, Tochikura T, Sato T, Konno T, Hirayoshi K, Seki M, et al. Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J 1987; 6: 3379–84.Google Scholar
  218. 218.
    McFarland HF, Goodman A, Jacobson S. Virus-specific cytotoxic T cells in multiple sclerosis. Ann NY Acad Sci 1988; 532: 273–9.PubMedGoogle Scholar
  219. 219.
    Plata F, Dadaglio G, Chenciner N, Hoffenbach A, Wain-Hobson S, Michel F, Langlade Demoyen P. Cytotoxic T lymphocytes in HIV-induced disease: implications for therapy and vaccination. Immunodefic Rev 1989; 1: 227–46.PubMedGoogle Scholar
  220. 220.
    Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248: 701–2.PubMedGoogle Scholar
  221. 221.
    Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44: 959–68.PubMedGoogle Scholar
  222. 222.
    Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989; 7: 601–24.PubMedGoogle Scholar
  223. 223.
    Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2 [published erratum appears in Cell 1994 Jan 28; 76:following 410]. Cell 1993; 75: 693–708.PubMedGoogle Scholar
  224. 224.
    Utz U, Koenig S, Coligan JE, Biddison WE. Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. J Immunol 1992; 149: 214–21.PubMedGoogle Scholar
  225. 225.
    Parker KC, DiBrino M, Hull L, Coligan JE. The beta 2-microglobulin dissociation rate is an accurate measure of the stability of MHC class I heterotrimers and depends on which peptide is bound. J Immunol 1992; 149: 1896–904.PubMedGoogle Scholar
  226. 226.
    Sakai K, Zamvil SS, Mitchell DJ, Hodgkinson S, Rothbard JB, Steinman L. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc Natl Acad Sci USA 1989; 86: 9470–4.PubMedGoogle Scholar
  227. 227.
    Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell 1989; 59: 247–55.PubMedGoogle Scholar
  228. 228.
    Holoshitz J, Frenkel A, Ben-Nun A, Cohen IR. Autoimmune encephalomyelitis (EAE) mediated or prevented by T lymphocyte lines directed against diverse antigenic determinants of myelin basic protein. Vaccination is determinant specific. J Immunol 1983; 131: 2810–3.PubMedGoogle Scholar
  229. 229.
    Klinman DM, Nutman TB. ELISPOT assay to detect cytokine-secreting murine and human cells. Klinman and Nutman, eds. Current Protocols in Immunology. London: John Wiley & Sons, 1994.Google Scholar
  230. 230.
    Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S. Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J Immunol 1998; 161: 482–8.PubMedGoogle Scholar
  231. 231.
    Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, et al. Direct visualization of antigen-specific T cells: HTLV-1 Tax 11–19-specificCD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci USA 1998; 95: 7568–73.PubMedGoogle Scholar
  232. 232.
    Bieganowska K, Hollsberg P, Buckle GJ, Lim DG, Greten TF, Schneck J, et al. Direct analysis of viral-specific CD8+ T cells with soluble HLA- A2/Tax 11–19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J Immunol 1999; 162: 1765–71.PubMedGoogle Scholar
  233. 233.
    Horvat B, Loukides JA, Anandan L, Brewer E, Flood PM. Production of interleukin 2 and interleukin 4 by immune CD4- CD8+ and their role in the generation of antigen-specific cytotoxic T cells. Eur J Immunol 1991; 21: 1863–71.PubMedGoogle Scholar
  234. 234.
    Widmer MB, Acres RB, Sassenfeld HM, Grabstein KH. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). J Exp Med 1987; 166: 1447–55.PubMedGoogle Scholar
  235. 235.
    Matsui M, Kuroda Y. Relevance of humoral and cellular immunity in the central nervous system in HAM/TSP. J Neuroimmunol 1994; 54: 180.Google Scholar
  236. 236.
    Elovaara I, Utz U, Smith S, Jacobson S. Limited T cell receptor usage by HTLV-I tax-specific, HLA class I restricted cytotoxic T lymphocytes from patients with HTLV-I associated neurological disease. J Neuroimmunol 1995; 63: 47–53.PubMedGoogle Scholar
  237. 237.
    Furukawa K, Mori M, Ohta N, Ikeda H, Shida H, Shiku H. Clonal expansion of CD8+ cytotoxic T lymphocytes against human T cell lymphotropic virus type I (HTLV-I) genome products in HTLV I-associated myelopathy/tropical spastic paraparesis patients. J Clin Invest 1994; 94: 1830–9.PubMedGoogle Scholar
  238. 238.
    Kuroda Y, Matsui M, Kikuchi M, Kurohara K, Endo C, Yukitake M, et al. In situ demonstration of the HTLV-I genome in the spinal cord of a patient with HTLV-I-associated myelopathy. Neurology 1994; 44: 2295–9.PubMedGoogle Scholar
  239. 239.
    Levin MC, Lehky TJ, Flerlage AN, Katz D, Kingma DW, Jaffe ES, et al. Immunologic analysis of a spinal cord-biopsy specimen from a patient with human T-cell lymphotropic virus type I-associated neurologic disease. N Engl J Med 1997; 336: 839–45.PubMedGoogle Scholar
  240. 240.
    Offner H, Buenafe AC, Vainiene M, Celnik B, Weinberg AD, Gold DP, et al. Where, when, and how to detect biased expression of disease-relevant V beta genes in rats with experimental autoimmune encephalomyelitis. J Immunol 1993; 151: 506–17.PubMedGoogle Scholar
  241. 241.
    Hara H, Morita M, Iwaki T, Hatae T, Itoyama Y, Kitamoto T, et al. Detection of human T lymphotrophic virus type I (HTLV-I) proviral DNA and analysis of T cell receptor V beta CDR3 sequences in spinal cord lesions of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Exp Med 1994; 180: 831–9.PubMedGoogle Scholar
  242. 242.
    Hoger TA, Jacobson S, Kawanishi T, Kato T, Nishioka K, Yamamoto K. Accumulation of human T lymphotropic virus (HTLV)-I-specific T cell clones in HTLV-I-associated myelopathy/tropical spastic paraparesis patients. J Immunol 1997; 159: 2042–8.PubMedGoogle Scholar
  243. 243.
    Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2 [comment]. Nature 1996; 384: 134–41.PubMedGoogle Scholar
  244. 244.
    Wucherpfenning KW, Hollsberg P, Richardson JH, Benjamin D, Hafler DA. T-cell activation by autologous human T-cell leukemia virus type I-infected T-cell clones. Proc Natl Acad Sci USA 1992; 89: 2110–4.Google Scholar
  245. 245.
    Kubota R, Soldan SS, Martin R, Jacobson S. An altered peptide ligand antagonizes antigen-specific T cells of patients with human T lymphotropic virus type I-associated neurological disease. J Immuno12000; 164: 5192–8.Google Scholar
  246. 246.
    Ijichi S, Izumo S, Eiraku N, Machigashira K, Kubota R, Nagai M, et al. An autoaggressive process against bystander tissues in HTLV-I-infected individuals: a possible pathomechanism of HAM/TSP. Med Hypotheses 1993; 41: 542–7.PubMedGoogle Scholar
  247. 247.
    Kubota R, Osame M, Jacobson S. Effects of microbes on the immune system. In: Cunningham MW, Fujinami RS (eds). Effects of Microbes on the Immune System. Philadelphia: Lippincott Williams & Wilkins, 2000, pp. 349–71.Google Scholar
  248. 248.
    Hollsberg P. Pathogenesis of chronic progressive myelopathy associated with human T-cell lymphotropic virus type I. Acta Neurol Scand Suppl 1997; 169: 86–93.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2001

Authors and Affiliations

  • Samantha S. Soldan
  • Steven Jacobson

There are no affiliations available

Personalised recommendations